Forteo(Teriparatide) Instructions:Uses,Dosage, Side Effects

1 / 1

Forteo(Teriparatide)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Eli Lilly and Company

Formulation:

INJECTION

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Teriparatide Injection is an anabolic agent used to treat osteoporosis in high-risk populations, including postmenopausal women, men with primary or hypogonadal osteoporosis, and patients on long-term glucocorticoids. It mimics parathyroid hormone to stimulate bone formation, increasing bone density and reducing fracture incidence. Administered as a once-daily subcutaneous injection via a prefilled pen, it requires adjunctive calcium and vitamin D. Key safety considerations include a boxed warning for osteosarcoma risk (based on rodent studies) and transient hypercalcemia. Therapy is limited to 2 years unless fracture risk persists.

Generic name

Forteo(Teriparatide)

English name

Teriparatide

Alternative Names

Forteo

Drug prices

Indications

1. Treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as having a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures.

2. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.

3. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.

Therapeutic Target

FORTEO targets bone formation by preferentially stimulating osteoblastic activity over osteoclastic activity, leading to increased bone mass, improved trabecular microarchitecture, and increased bone strength.

Active Ingredients

Teriparatide, a recombinant human parathyroid hormone analog (PTH 1-34) with molecular formula C₁₈₁H₂₉₁N₅₅O₅₁S₂ and molecular weight of 4117.8 daltons.

Dosage form

INJECTION

specifications

250 micrograms/mL/box

Description

FORTEO (teriparatide injection) is a recombinant human parathyroid hormone analog (PTH 1-34) manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Each mL contains 250 mcg of teriparatide (as a free base), 0.41 mg of glacial acetic acid, 0.1 mg of sodium acetate (anhydrous), 45.4 mg of mannitol, 3 mg of Metacresol, and Water for Injection. Hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the pH to 4.

Dosage and Administration

1. Recommended Dosage:

1.1 20 mcg subcutaneously once a day.

1.2 Consider supplemental calcium and Vitamin D based on individual patient needs.

2. Administration Instructions:

2.1 Administer as a subcutaneous injection into the thigh or abdominal region.

2.2 Administer initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur.

2.3 Inspect visually for particulate matter and discoloration prior to administration (FORTEO is a clear and colorless liquid).

2.4 Patients and/or caregivers should receive appropriate training and instruction on proper use.

2.5 Discard the delivery device 28 days after first use.

3. Treatment Duration:

Use of FORTEO for more than 2 years during a patient's lifetime should only be considered if a patient remains at or has returned to having a high risk for fracture.

CATEGORY NAVIGATION